The polymorphic inheritance of DIO2 rs225014 may predict body weight variation after Graves' disease treatment
Arch. endocrinol. metab. (Online)
; 64(6): 787-795, Nov.-Dec. 2020. tab, graf
Article
en En
| LILACS
| ID: biblio-1142197
Biblioteca responsable:
BR1.1
ABSTRACT
ABSTRACT Objective:
We aimed to investigate the role of DIO2 polymorphisms rs225014 and rs12885300 in Graves' disease patients, mainly for controlling body weight following treatment. Subjects andmethods:
We genotyped 280 GD patients by the time of diagnosis and 297 healthy control individuals using a TaqMan SNP Genotyping technique. We followed up 141 patients for 18.94 ± 6.59 months after treatment.Results:
There was no relationship between the investigated polymorphisms with susceptibility to GD and gain or loss of weight after GD treatment. However, the polymorphic inheritance (CC+CT genotype) of DIO2 rs225014 was associated with a lower body weight variation after GD treatment (4.26 ± 6.25 kg) when compared to wild type TT genotype (6.34 ± 7.26 kg; p = 0.0456 adjusted for the follow-up time). This data was confirmed by a multivariate analysis (p = 0.0138) along with a longer follow-up period (p = 0.0228), older age (p = 0.0306), treatment with radioiodine (p-value = 0.0080) and polymorphic inheritance of DIO2 rs12885300 (p = 0.0306).Conclusion:
We suggest that DIO2 rs225014 genotyping may have an auxiliary role in predicting the post-treatment weight behavior of GD patients.Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Peso Corporal
/
Enfermedad de Graves
/
Predisposición Genética a la Enfermedad
/
Yoduro Peroxidasa
/
Radioisótopos de Yodo
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Arch. endocrinol. metab. (Online)
Asunto de la revista:
ENDOCRINOLOGIA
/
METABOLISMO
Año:
2020
Tipo del documento:
Article